The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

HHV-6 Reactivation

Human herpesvirus 6 reactivation in transplant and immunocompromised hosts

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is HHV-6 Reactivation?

HHV-6 is a beta-herpesvirus existing in two species (HHV-6A and HHV-6B) that primarily infect children, causing roseola infantum (HHV-6B). After primary infection, the virus establishes lifelong latency in lymphocytes, monocytes, and tissues. In immunocompromised hosts (especially allogeneic HSCT), reactivation occurs in 40-60% of recipients within the first 4-6 weeks post-transplant.

Approximately 1% of the population has chromosomally integrated HHV-6 (ciHHV-6) in every cell, leading to persistently elevated PCR levels (typically over 5.5 log10 copies/mL whole blood) without true active infection. Distinguishing reactivation from ciHHV-6 is essential before initiating antiviral therapy and requires comparing whole blood, plasma, and high-titer testing of donor and recipient.

Clinical manifestations include limbic encephalitis (most distinctive, with anterograde amnesia, seizures, and characteristic mesial temporal MRI signal abnormalities), encephalopathy, fever of unknown origin, bone marrow suppression (especially after engraftment), hepatitis, pneumonitis, and rash. Treatment with foscarnet or ganciclovir is reserved for symptomatic disease or persistently high viral loads in high-risk patients. Recent guidelines emphasize preemptive over routine prophylactic strategies.

Symptoms

Often asymptomatic reactivation
Fever of unknown origin
Bone marrow suppression (cytopenia after engraftment)
Delayed engraftment
Limbic encephalitis (anterograde amnesia, confusion, seizures)
Mesial temporal lobe MRI signal changes
Encephalopathy, altered mental status
Seizures, status epilepticus
Hepatitis (elevated transaminases)
Pneumonitis
Rash
Hyponatremia (SIADH)
Graft-versus-host disease exacerbation
Bone marrow graft dysfunction
Multifocal neurologic signs
Headache
Confusion, disorientation
Memory deficits, particularly short-term
Behavioral changes
Delayed neurologic recovery

Risk Factors

Allogeneic HSCT (highest risk: cord blood, T-cell depleted, haploidentical, mismatched donor)
Pre-transplant conditioning intensity
Acute graft-versus-host disease (GVHD)
Anti-thymocyte globulin (ATG) use
Corticosteroid therapy
Pediatric HSCT (higher than adult)
Solid organ transplantation
HIV with severe immunosuppression
Chronic lymphoproliferative disease
Anti-CD52 (alemtuzumab)
JAK inhibitor therapy
Multiple sclerosis (controversial association)
Chronic fatigue syndrome (controversial)
Drug reaction with eosinophilia and systemic symptoms (DRESS)
Severe COVID-19 (reactivation)
Critically ill ICU patients
Chemotherapy
Engraftment period (weeks 2-6 post-HSCT)
ChromosomalIy integrated HHV-6 (germline integration)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • HSCT recipient with new neurologic symptoms
  • Fever of unknown origin in transplant patient
  • New altered mental status, seizures, or memory deficits in immunocompromised patient
  • Delayed or failing engraftment
  • Cytopenia developing post-engraftment without clear cause
  • Hepatitis in transplant recipient
  • Pneumonitis in transplant recipient
  • Routine post-HSCT surveillance
  • DRESS syndrome with neurologic features
  • Critically ill patient with unexplained encephalopathy

Treatment Methods

01
Quantitative HHV-6 plasma and whole blood PCR with comparison to distinguish reactivation from ciHHV-6
02
CSF PCR for suspected encephalitis (interpret with concurrent blood PCR)
03
Brain MRI showing mesial temporal signal changes (T2/FLAIR hyperintensity)
04
EEG for seizure activity
05
Comprehensive evaluation: CBC, comprehensive metabolic panel, hepatic function, ammonia
06
Lumbar puncture with cell count, protein, glucose, viral PCR panel
07
Investigation for ciHHV-6 (compare donor and recipient PCR levels, whole blood vs plasma ratio, hair follicle DNA)
08
Routine post-HSCT surveillance with weekly plasma PCR in high-risk recipients
09
Preemptive therapy initiation for symptomatic disease or persistently high viral load (over 4 log10 copies/mL plasma)
10
Foscarnet 60-90 mg/kg IV every 8-12 hours for 2-3 weeks (preferred for encephalitis)
11
Ganciclovir 5 mg/kg IV every 12 hours as alternative
12
Cidofovir as third-line agent
13
Reduction of immunosuppression when possible
14
Anticonvulsants for seizures
15
Supportive care including ICU management for severe disease
16
Treatment of coinfections (CMV, EBV, fungal) common in this population
17
IVIG as adjunct in selected cases (limited evidence)
18
Renal monitoring with foscarnet (nephrotoxicity, electrolyte abnormalities)
19
Bone marrow toxicity monitoring with ganciclovir
20
Long-term neurologic follow-up for cognitive and memory recovery
21
Multidisciplinary care including transplant infectious disease, neurology, hematology
22
No specific HHV-6 vaccine available; transmission via saliva universal in childhood

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.